Clinical Determinants and One Year Follow-Up of Dementia and Mild Cognitive Impairment following Ischemic Stroke. by Murugapandian, N
 A STUDY ON CLINICAL DETERMINANTS AND ONE YEAR 
FOLLOW-UP OF DEMENTIA AND MILD COGNITIVE 
IMPAIRMENT FOLLOWING ISCHEMIC STROKE 
 
Dissertation submitted to 
THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY 
 
 
in partial fulfilment of the requirements  
for the award of the degree of 
DM (NEUROLOGY) – BRANCH – I 
 
 
 
 
 
 
 
 
THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
 
AUGUST 2011 
 
CERTIFICATE 
        This is to certify that the Dissertation entitled, “CLINICAL 
DETERMINANTS AND ONE YEAR FOLLOW-UP OF DEMENTIA AND 
MILD COGNITIVE IMPAIRMENT FOLLOWING ISCHEMIC STROKE” is the 
bonafide record work done by Dr.N.Murugapandian, under our guidance and 
supervision in the Institute of Neurology, Rajiv Gandhi Government General Hospital, 
Madras Medical College, Chennai, submitted as partial fulfilment for the requirements 
of D.M. Degree examination Branch I NEUROLOGY, AUGUST 2011, under The 
Dr.M.G.R. Medical University, Chennai. 
 
DR.R.M.BHOOPATHY .DM.                                                                                
PROFESSOR  OF NEUROLOGY,                                                                              
INSTITUTE OF NEUROLOGY,                                                                                           
MADRAS MEDICAL COLLEGE,                                                                                         
CHENNAI-3 
 
DR.V.SUNDAR. Mch.                                                                                           
PROFESSOR AND HEAD OF THE DEPARTMENT,                                                                              
INSTITUTE OF NEUROLOGY,                                                                                           
MADRAS MEDICAL COLLEGE,                                                                                         
CHENNAI-3 
 
 
 
Dr.V.KANAGASABAI, M.D., 
THE DEAN, 
MADRAS MEDICAL COLLEGE, 
CHENNAI-3.                                         
 
DECLARATION 
 
 I solemnly declare that this dissertation titled “CLINICAL 
DETERMINANTS AND ONE YEAR FOLLOW-UP OF DEMENTIA 
AND MILD COGNITIVE IMPAIRMENT FOLLOWING 
ISCHEMIC STROKE” is done by me in the Institute of Neurology, 
Madras Medical College & Rajiv Gandhi Government General Hospital, 
Chennai under the guidance and supervision of Prof. Dr.R.M. Bhoopathy, 
M.D., D.M., Professor of Neurology, Institute of Neurology, Madras 
Medical College & Rajiv Gandhi Government General Hospital, Chennai. 
This dissertation is submitted to the Tamil Nadu Dr.M.G.R Medical 
University, Chennai in partial fulfilment of the university requirements for 
the award of the degree of D.M. Neurology. 
 
Place : Chennai 
Date  :                                             
 
Dr.N.Murugapandian. 
D.M.Postgraduate student, 
Institute of  Neurology,  
Madras medical college,  
Chennai.       
 
 
 
 
 
ACKNOWLEDGEMENT 
 It gives me great pleasure to acknowledge all those who guided, 
encouraged and supported me in the successful completion of my 
dissertation. 
           First and foremost, I express my gratitude to, the Dean 
Dr.V.Kanagasabai M.D.for having permitted me to carry out this 
dissertation work at Rajiv Gandhi Government General Hospital, Madras 
Medical College, Chennai.  
I am extremely thankful to Prof. Dr.V.Sundar.M.ch., Professor of 
Neurosurgery, Head of the department, Institute of Neurology, Rajiv 
Gandhi Government General Hospital Chennai for his constant 
encouragement, valuable guidance and support. 
 I express my deep sense of gratitude and sincere thanks to our 
respected and beloved Chief Dr.  R.M. Bhoopathy. M.D.,  D.M., Professor 
of Neurology,  Institute  of  Neurology, Rajiv Gandhi Government General 
Hospital Chennai  for his teaching, valuable suggestions, constant 
motivation,  kind guidance and  moral support in the conduct of this study. 
          I express my sincere thanks and gratitude to our Professors    
Dr.C.Mutharasu.D.M., Dr.K.Bhanu.D.M., Dr.R.LakshmiNarasimhan.D.M,                   
Dr. S. Balasubramanian. D.M., for their valuable suggestions and support. 
        I am extremely thankful to our Assistant Professors 
Dr.V.Kamaraj,D.M., Dr.S.Arunan..D.M., Dr.M.Jawahar.D.M., 
Dr.P.Muthukumar.D.M., Dr. V.Kannan.D.M.,  for their valuable guidance 
and support. 
 I owe my sincere thanks to all those patients and the technical staffs 
who participated in the study for it is their cooperation which made this 
study possible. 
 
 
CONTENTS 
S.No. Title Page No. 
1   INTRODUCTION 1 
2   REVIEW OF LITERATURE 3 
3   AIM AND OBJECTIVES 38 
4   MATERIALS AND METHODS 39 
5   RESULTS  46 
6   DISCUSSION 58 
7   CONCLUSION 68 
8   REFERENCES  
9   APPENDICES  
 
 LIST OF ABBREVIATIONS 
 
NCI      -    No Cognitive Impairment 
VaMCI -    Vascular Mild Cognitive Impairment 
VaD      -    Vascular Dementia 
MCI      -    Mild Cognitive Impairment     
CT         -   Computerized Tomogram 
MRI      -    Magnetic Resonance Imaging 
MMSE  -    Mini Mental Status Examination   
BNT      -    Boston Naming Test 
RAVLT -    Rey Auditory Verbal Learning Test    
BI          -    Barthel Index 
ADL      -    Activities of Daily Living 
ACA      -    Anterior Cerebral Artery 
MCA      -     Middle Cerebral Artery 
PCA       -     Posterior Cerebral Artery 
 
1 
 
INTRODUCTION 
Cognitive impairment due to cerebrovascular disease is termed 
“Vascular Cognitive Impairment” and forms a spectrum that includes 
Vascular Dementia and milder forms of cognitive impairment referred to 
as Vascular Mild Cognitive Impairment.[1] While Vascular Dementia is 
the second most common cause of dementia, the milder form Vascular 
Mild Cognitive Impairment is much more common. Nearly half of 
individuals with Vascular Mild Cognitive Impairment convert to 
dementia after five years.[2] Vascular cognitive disorders are poised to 
become the silent epidemic of the 21st century and contribute 
significantly to mortality, disability, and decreased quality of life.[3]  
It is now clear that Vascular Cognitive Impairment is not a single 
entity, but represents a complex neurological disorder that occurs as a 
result of interaction between vascular risk factors and brain parenchymal 
changes such as macro and micro infarcts, haemorrhages, white matter 
changes, and brain atrophy occurring in an ageing brain.  
Factors that determine progression of milder form Vascular Mild 
Cognitive Impairment to dementia are not well understood. Since 
Vascular Cognitive Impairment is amenable to prevention and treatment, 
there is a pressing need to identify factors that protect or predispose to it. 
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Dementia is a common sequelae of stroke with a frequency ranging 
from 16% to 32%. [4–5] In a more recent epidemiological study, the 10-
year risk of dementia after stroke was estimated at 19.3%, compared to 
11.0% in non-stroke controls. [6] This twofold increase in dementia 
following stroke is in contrast with a nine fold increase reported in some 
previous studies. [7] The large variation in rates is accounted for by 
variations in the populations studied as well as the criteria used for the 
diagnosis of dementia. As the definition of vascular dementia is currently 
being refined, [8] it is timely that these studies be revisited. One aspect of 
this reassessment is the consideration of vascular mild cognitive 
impairment in stroke patients, which has thus far received little attention.  
Most studies on post stroke cognitive impairment have focused on 
dementia. Bowler and Hachinski a decade ago made warnings about the 
limitations of the diagnostic category of vascular dementia and coined the 
term vascular cognitive impairment to refer to any cognitive impairment 
related to cerebrovascular disease.  Detection of cognitive impairment has 
two difficulties: a neuropsychologic battery fitted to the vascular 
cognitive impairment profile is yet to be established and limits from 
normal cognition are still undefined. Also, the evidence of the vascular 
origin of cognitive impairment is difficult to ascertain. 
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REVIEW OF LITREATURE 
DEFINITIONS 
Vascular dementia: Vascular dementia is the loss of cognitive 
functions to a degree that interferes with Activities of Daily Livings, 
resulting from ischemic or hemorrhagic cerebrovascular disease or from 
cardiovascular or circulatory disturbances that injure brain regions that 
are important for memory, cognition, and behaviour. [9] Vascular 
dementia is the second most common form of dementia after Alzheimer’s 
disease, accounting for approximately 20% of dementia cases worldwide.  
Globally, Vascular dementia  is more common in men, especially 
before age 75—in contrast with Alzheimer’s disease that predominates in 
women—and is more prevalent in populations that are affected by 
cerebral small-vessel disease, such as Asians, Blacks, and Hispanics. In 
keeping with the predictions of increasing burden of stroke and heart 
disease in the near future, Vascular dementia will probably become the 
most common cause of senile dementia, both by itself and as a 
contributor to other degenerative dementias.[10] 
Vascular mild cognitive impairment: Vascular mild cognitive 
impairment is a recently coined term to signify any degree of cognitive 
loss caused by cerebrovascular disease, including vascular dementia. 
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However, by analogy with mild cognitive impairment (MCI) resulting 
from Alzheimer’s disease, the term Vascular Cognitive Impairment is 
better reserved for patients with risk factors for cerebrovascular disease  
and some degree of cognitive loss short of dementia. 
 Intrinsic to the Vascular Cognitive Impairment concept is the hope 
that appropriate prevention and treatment of cerebrovascular disease can 
prevent Vascular dementia  development. Although this is an appealing 
undertaking, there have been difficulties in providing a strict definition of 
Vascular Cognitive Impairment and operational diagnostic criteria. The 
concept of Vascular Cognitive Impairment suffers from the same 
problems once criticized in Vascular dementia ; i.e., the notion is too 
wide and too vague for a precise operative definition. Furthermore, as 
demonstrated in the Canadian Study on Health and Aging, [11] some 
patients with a diagnosis of Vascular Cognitive Impairment no dementia 
improved with time, indicating that progression from Vascular Cognitive 
Impairment to Vascular dementia may not always be a unidirectional 
pathway. There is growing evidence that preventive measures to decrease 
the vascular burden on the brain may also decrease Vascular dementia, as 
well as Alzheimer’s disease.   
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Mixed dementia: The boundaries between Vascular dementia and 
Alzheimer’s disease recently have become indistinct. The belief that 
CVD may lead to cognitive decline and dementia in the elderly has been 
around since 1672, when Thomas Willis first described cases of 
postapoplectic dementia. Less well recognized is that silent strokes and 
incomplete white matter ischemia—documented by modern brain 
imaging—are also strongly associated with cognitive loss, behavioural 
changes, and Vascular dementia .  
During most of the past two centuries, it was widely held that 
atherosclerotic dementia was the sole cause of senile dementia. It was 
only in the 1980s that Alzheimer’s disease was declared the most 
common form of dementia in the elderly. However, most elderly patients 
with dementia who are autopsied will have amyloid plaques and 
neurofibrillary tangles, the typical brain lesions of Alzheimer’s disease, 
localized in the hippocampal regions (Braak Stages I–III), coexisting with 
cerebrovascular lesions, such as large and small strokes, hemorrhages, 
arteriolosclerosis, lacunes, microinfarcts, and ischemic 
leukoencephalopathy.  
Cerebrovascular disease is required to “amplify” the clinical 
expression of Alzheimer’s disease pathology beyond the stage of 
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amnestic MCI (Braak Stage III). This explains why almost 20% of cases 
pathologically defined by Consortium to Establish a Registry for 
Alzheimer Disease (CERAD) criteria as Alzheimer’s disease do not have 
clinical dementia. Conversely, more than half of the octogenarians 
without dementia meet CERAD criteria for pathologically confirmed 
Alzheimer’s disease. On the other hand, Hénon and colleagues,[12] have 
also shown that in patients with bonafide postapoplectic Vascular 
dementia , pre-existing amnestic deficits occurred in 16% of cases, 
suggesting that the underlying Alzheimer’s disease had not progressed 
beyond Stage III, which is clearly insufficient to produce clinical 
dementia. Evidence from the Nun Study also concluded that lacunes 
increase more than 20 times the risk of clinical expression of dementia at 
early Braak stages that are insufficient to produce dementia. Moreover, in 
pathologically confirmed cases of “mixed” dementia (Alzheimer’s 
disease +Cerebrovascular Disease, Alzheimer’s disease +Vascular 
dementia), there is a significant inverse relationship between the severity 
of cerebrovascular disease and Braak stage. In all these patients, Vascular 
dementia is the defining cause of the dementia.  
In addition, population-based studies have shown that silent 
lacunes are extremely common in the elderly. Longstreth et al. showed 
the presence of one or more silent lacunes in approximately one fourth of 
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the 3,660 participants in the Cardiovascular Health Study (CHS) aged 65 
and older that underwent cerebral magnetic resonance imaging (MRI). 
Recently, in the Rotterdam cohort, Vermeer et al. demonstrated that the 
presence of lacunes, particularly in the thalamus, more than doubled the 
risk of dementia (hazard ratio = 2.26, 95% CI, 1.09–4.70). Small-vessel 
disease may be the most common mechanism to convert from MCI into 
Alzheimer’s disease in persons over the age of 70 years. 
WHEN TO SUSPECT VASCULAR COGNITIVE IMPAIRMENT 
Typically, patients with vascular cognitive impairment are not 
found in memory disorder clinics, because memory loss is a less 
prominent manifestation of this syndrome. This must be considered when 
extrapolating figures of dementia prevalence from hospital- or office-
based data. This also explains the alleged rarity of vascular cognitive 
impairment in neuropathologically examined specimens from brain banks 
of Alzheimer’s Disease clinics. Primary care settings are the main referral 
source of patients with vascular cognitive impairment. The vascular 
cognitive impairment should be suspected in any patients presenting with 
cognitive impairment and various risk factors (Table.1) 
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Table.1. Risk Factors for Vascular Dementia  
1. Advanced age   
2. Long-term, untreated 
arterial 
3. hypertension    
4. Isolated systolic 
hypertension 
5. in the elderly 
6. Diabetes mellitus  
7. Cigarette smoking  
8. Hyperlipidemia   
9. Hyperhomocysteinemia 
10. Hyperfibrinogenemia  
11. Atrial fibrillation 
12. Other cardiac arrhythmias 
13. Complicated stroke 
14. Recurrent stroke 
15. Orthostatic hypotension 
16. Obstructive sleep apnea 
17. Major surgery in the 
elderly 
18. Coronary artery graft 
Surgery 
 
Cortical and Subcortical Dementias: Clinicians divide the dementia 
syndrome into two main types, cortical and subcortical, according to the 
clinical features and the pattern of neuropsychological impairment. The 
prototypical cortical dementia is Alzheimer’s Disease that manifests 
preponderantly with early and severe memory disturbances, aphasia, 
agnosia, and apraxia resulting from lesions involving posterior cortical 
association regions. In sharp contrast, Vascular Dementia manifestations, 
a typical subcortical dementia, include slowing of cognition and motor 
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function owing to executive control, along with prominent alterations of 
gait, speech, affect, and mood. The manifestations mentioned result from 
the interruption by ischemic lesions of frontal cortico-subcortical circuits 
(see Fig. 1) for executive control of memory, language, mood, 
constructional skills, motivation, and socially responsive  behaviors.  
THE NEUROPATHOLOGIC SUBSTRATES OF VASCULAR-
ISCHEMIC DEMENTIA  
Fundamental pathological lesions in Vascular Cognitive 
Impairment consist of atherosclerosis with or without thrombosis/ 
thromboembolism of extracerebral and intracerebral arteries, intracerebral 
microangiopathies—arteriosclerotic, hyalinotic, inflammatory, and 
amyloid-related—often combined with systemic factors that may produce 
small and large infarcts and several forms of white matter degeneration. 
The extent and location of cerebrovascular lesions and destroyed tissues, 
which differ considerably from case to case, multiplicity, and bilateral 
occurrence, are the most important factors underlying cognitive 
impairment.  
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Figure 1. Frontal-subcortical-thalamic circuits 
 
One of the most controversial and incompletely understood issues 
is the degree to which vascular pathology contributes to dementia. 
Complicating the postmortem Vascular Cognitive Impairment diagnosis 
are other pathologic entities coexisting with vascular lesions that could 
lead to cognitive decline. Many of these can be found at postmortem 
examination, particularly in multimorbid elderly subjects.   
However, it should be emphasized that the presence of 
cerebrovascular lesions at autopsy does not prove that they cause 
cognitive decline, underscoring that thorough clinicopathologic 
correlation is essential to establish a definite diagnosis. Although several 
class I and II studies that compared clinical diagnosis and 
neuropathologic findings in reference cohorts, which are similar to 
11 
 
population-based studies, reported low sensitivity and specificity for the 
currently used clinical diagnostic Vascular Cognitive Impairment criteria 
with variable interrater reliability.  According to recent clinicopathologic 
studies, The Mayo Clinic criteria (temporal relationship between stroke 
and dementia or worsening or bilateral infarctions in specified locations) 
had 75% sensitivity and 81% specificity for pure Vascular Dementia.  
Because the criteria chosen to diagnose Vascular Dementia will 
influence estimates on its incidence and prevalence, as well as its 
recognition and treatment, new research criteria (e.g., for subcortical 
Vascular Dementia) have been proposed, and the need for prospective 
clinicopathologic correlation studies has been emphasized. These criteria 
can only be established at autopsy in patients who have been thoroughly 
and longitudinally evaluated before death and who do not have other 
causes of dementia.  
Vascular Cognitive Impairment is related to a variety of pathologic 
lesions, the clinical significance of which and their relation to 
Alzheimer’s Disease and other age-related changes of the brain (e.g., 
subcortical white matter lesions) remain controversial.  However, we are 
not aware of any validation study of the neuropathologic Vascular 
Cognitive Impairment criteria. 
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Although causal relationships between certain cerebrovascular 
lesions and dementia evade strict classifications and no classification of 
brain lesions causing cognitive impairment is ideal, the major 
cerebrovascular lesions associated with cognitive impairment are 
summarized below. 
Major Morphological Types of Vascular Dementia: 
1. Classical multiinfarct encephalopathy (MIE) Multiple large 
(sub/territorial) infarcts in cortex and white matter/basal ganglia in 
territories of large cerebral arteries, MCA, MCA plus PCA; 
involving left or both hemispheres. 
2. Strategic infarct dementia (SID) Small or medium-sized 
infarcts/ischemic scars in functionally important brain regions: 
thalamus; hippocampus (PCA), basal forebrain angular gyrus 
(ACA), bilaterally or dominant hemispheres. 
3. Microangiopathic (small vessel infarct) dementia (SMVA) 
a. Subcortical arteriosclerotic leukoencephalopathy 
Binswanger (SAE) Multiple small infarcts in basal ganglia 
plus white matter with preservation of cortex 
b. Multilacunar state Multiple microinfarcts (scars up to 1.5 
cm); basal ganglia, hemispheral white matter, pontine basis 
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Multiple cortico-subcortical microinfarctions (mixed 
encephalopathies) 
c. Granular cortical atrophy Multiple small scars within 
border zones ACA MCA in one/both hemispheres 
4. Subcortical microvascular leukoencephalopathy 
(acquired/genetically determined) 
5. Gliosis or hippocampal sclerosis 
6. Inflammatory angiopathy and other mechanisms 
Dementia Associated With Cerebrovascular Disease: 
A. Multifocal/diffuse disease 
1. Multiple atherosclerotic/watershed infarcts (large 
artery/border zone territories) 
2. Anti-PL-related ischemia 
3. “Granular atrophy” of cortex (multifocal cortical 
microinfarcts) 
4. Multiple lacunar infarcts (resulting from microvascular 
disease or microatheroma) 
5. Binswanger subcortical leukoencephalopathy (BSLE)  
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6. CADASIL 
7. Angiitis 
8. Cerebral amyloid angiopathy (CAA) plus/minus infarcts, 
hemorrhages (Alzheimer’s Disease variant?)—Familial 
forms,including Dutch, Icelandic, British 
9. Miscellaneous angiopathies (FMD, Moyamoya) 
10. Cortical laminar necrosis (post-cardiac arrest, 
hypotension) 
11. Extreme dilatation/enlargement of brain parenchymal 
perivascular spaces 
B. Focal disease/strategically placed infarcts 
1. Mesial temporal (including hippocampal) 
infarcts/ischemia/sclerosis 
2. Caudate and thalamic infarcts (especially DM nucleus, 
bilateral damage) 
3. Fronto-cingulate infarcts (ACA territory) 
4. Angular gyrus infarct (dominant cerebral hemisphere) 
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THE COGNITIVE PROFILE OF VASCULAR DEMENTIA 
A review of the literature on neuropsychological functioning in 
Vascular Dementia makes clear that several, if not all, cognitive domains 
are affected when compared to normative data or normal control 
samples.To illustrate this point, Figure.2 depicts neurocognitive 
performances of patients with mild and severe Vascular Dementia. As the 
figure shows, the samples performed in the impaired range across all 
domains.Thus, the question arises whether there is a unique profile or 
cognitive aspect of Vascular Dementia. 
 Obviously, the nature and location of vascular neuropathology can 
impact cognitive functioning in the case of classic stroke syndromes. 
However, regarding small-vessel disease, it has been argued that 
impairment in executive functioning and relative preservation of 
recognition memory are necessary cognitive criteria for Vascular 
Dementia.[13] The executive deficits are a hallmark symptom of 
Vascular Dementia, which appear regardless of the presence or absence 
of cognitive dysfunction in other domains. An analogy can be drawn to 
the conceptualization of Alzheimer’s Disease, as memory-encoding 
difficulties have been referred to as the sine qua non of Alzheimer’s 
Disease. Although memory difficulties are not the only clinical 
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manifestation of Alzheimer’s Disease, it is widely believed that for most, 
but certainly not all, cases of Alzheimer’s Disease, memory dysfunction 
is an early and prominent symptom that is expressed throughout the 
course of the disease. With time, additional cognitive symptoms become 
apparent (e.g., deficits in language, praxis, construction, and executive 
function); however, memory disturbance is a cardinal feature of the 
disease. Similarly, many believe that executive deficits represent a 
common manifestation of Vascular Dementia.  
The neuroanatomic underpinnings of executive dysfunction in 
Vascular Dementia have traditionally been attributed to disruption of the 
frontal subcortical circuits initially outlined by Alexander and colleagues, 
who described a series of parallel but functionally segregated circuits that 
link subcortical structures to the frontal lobes. Perhaps the most relevant 
circuit to Vascular Dementia is that involving the dorsolateral prefrontal 
cortex, as the dysexecutive syndrome that emerges from damage to this 
pathway is the most common clinical presentation in Vascular Dementia. 
Indeed, there is some evidence that white matter disease in subcortical 
structures involved in this pathway (i.e., thalamus and basal ganglia) is 
associated with executive dysfunction in patients with Vascular 
Dementia. 
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INDIAN PERSPECTIVE 
In terms of population, India ranks second only to China. Recent 
rapid socioeconomic changes have led to a concomitant change in 
people’s lifestyle, leading to work-related stress and altered food habits, 
raising the risk of hypertension. Those factors, coupled with an increase 
in the average life expectancy, are expected to have an impact on the 
occurrence of stroke as well as stroke related complications in India.  
 
Figure. 2. Neurocognitive performances of patients with mild and severe 
vascular dementia in relation to hypothetical performances of patients 
with vascular cognitive impairment 
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Vascular cognitive impairment is a problem close to home. 
Developing countries have a rapidly ageing population and it is projected 
that 71% of dementia cases will be in the developing world. Vascular 
Dementia is the second most common cause of dementia accounting for 
39% of cases,[14] and hence, absolute numbers of Vascular Dementia, is 
high in India.[15]  
Cardiovascular disease burden is high in developing countries 
including India and has been attributed to the  increasing incidence of 
atherosclerotic diseases, perhaps due to urbanization, epidemiologic 
transition and higher risk factor levels, the relatively early age at which 
they manifest, the large sizes of the population, and the high proportion of 
individuals who are young adults or middle-aged in these countries.[16] 
Vascular risk factors has been demonstrated to be strongly associated 
with MCI in an epidemiologic study from Kolkata. Higher prevalence of 
vascular risk factors in India is likely to increase burden of Vascular 
Dementia and Vascular Mild Cognitive Impairment.  
Stroke, the overt manifestation of cerebrovascular disease is one of 
the most important risk factors for Vascular Dementia. Stroke burden is 
increasing rapidly in developing countries (124% and 107% increases in 
stroke mortality among men and women in developing countries versus 
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78% and 56% increases, respectively, in the developed countries). Studies 
have consistently shown that up to 64% of persons who have experienced 
a stroke have some degree of cognitive impairment[17] with up to a third 
developing frank dementia.[18] In a hospital-based study from 
Hyderabad, of 123 consecutive patients from the Stroke registry 
evaluated a minimum of 3 months after stroke, 91 (74%) were found to 
have cognitive impairment- 31% with Vascular Dementia and 43% with 
Vascular Mild Cognitive Impairment. A longitudinal follow-up of 50% of 
the group over a mean period of 13 months demonstrated that all patients 
with dementia at baseline continued to have dementia at follow-up and 
none of the cognitively normal patients worsened. Course of Vascular 
Mild Cognitive Impairment was variable-seven patients reverted to 
normal and one patient progressed to dementia.[19]  
Inadequate resources and low awareness coupled with growing 
numbers of patients with Vascular Mild Cognitive Impairment make it a 
problem that needs urgent attention on a priority basis. 
DIAGNOSIS  
The diagnosis of vascular cognitive impairment requires 
establishing the presence of cognitive impairment and its association with 
cerebrovascular disease. Identifying the presence and impact of cognitive 
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impairment involves the following steps: reporting of subjective 
symptoms, objective confirmation by neuropsychological and 
behavioural assessment, determination of severity of cognitive decline, 
and its functional impact on Activities of Daily Living. Cerebrovascular 
disease can be established by the clinical history of a stroke and the 
presence of focal neurological deficits corroborated by brain imaging. 
The mechanism underlying the stroke can be identified by the use of 
appropriate investigations, including Electrocardiogram, 2D 
Echocardiogram, extracranial and intracranial vascular imaging, and 
hematological investigations. The association between stroke and 
cognitive impairment is thought to be substantiated by a temporal 
relationship between the two and location of infarct in a region 
appropriate for cognitive impairment.  
Clearly a great degree of variability exists in the method of 
establishing all these features. This difficulty is evident from the various 
criteria that have been proposed for the diagnosis of Vascular Dementia. 
Majority of them have been devised based on consensus rather than 
clinical data. The Hachinski ischemic score (Table.2), a simple clinical 
tool that performs well in the differentiation between Alzheimer’s 
dementia and multi-infarct dementia, the purpose for which it was 
originally designed, but mixed dementia remains difficult. [20]  
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The four sets of criteria ( Table.3 &4) currently being used in 
clinical practice and research include International Classification of 
Diseases-10 ( ICD-10), Diagnostic and Statistic Manual-IV ( DSM-IV), 
State of California Alzheimer's Disease Diagnostic and Treatment 
Centres Centres (ADDTC), and the National Institute for Neurological 
Disorders and Stroke-Association Internationale pour la Recherche et 
a'Enseignement en Neurosciences (NINDS-AIREN) criteria. [21],[22] 
Cognitive impairment and presence of significant cerebrovascular disease 
are common to all criteria, but the method of establishing their presence 
and the causal relationship between them is variable. Studies evaluating 
the validity and reliability of these criteria have demonstrated that the 
existing criteria are not sufficiently sensitive, use different definitions of 
dementia, and are not easily interchangeable. [23] 
In an attempt to resolve this controversy, an attempt has been made 
to simplify the classification system based on clinical and imaging 
features. Vascular cognitive impairment, classified on the basis of clinical 
and imaging features into Vascular cognitive impairment without 
dementia, Vascular Dementia and mixed degenerative/ Vascular 
Dementia was found to be useful in a large hospital-based cohort of 
patients. [24]  
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In an attempt to harmonise methodology to identify and describe 
individuals with Vascular Cognitive Impairment, particularly in the early 
stages, the National Institute for Neurological Disorders and Stroke 
(NINDS) and the Canadian Stroke Network (CSN) developed common 
standards in clinical diagnosis, epidemiology, brain imaging, 
neuropathology, experimental models, genetics, and clinical trials to 
recommend minimum, common, clinical, and research standards for the 
description and study of vascular cognitive impairment. [25] Using the 
same standards was thought to help identify individuals in the early 
stages of cognitive impairment, make studies comparable, and integrate 
knowledge, thereby accelerating the pace of progress of understanding, 
preventing and treating Vascular Cognitive Impairment. 
Table.2 . Hachinski Ischemia Score 
Abrupt onset  2 
Stepwise deterioration 1 
Fluctuating course 2 
Nocturnal confusion 1 
Relative preservation of personality 1 
Depression 1 
Somatic complaints 1 
Emotional incontinence 1 
History of hypertension 1 
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History of strokes 2 
Evidence of associated 
atherosclerosis 
1 
Focal neurological symptoms 2 
Focal neurological signs 2 
Total score: --- 
 
Table.3. DSM-IV Criteria for the Diagnosis of Vascular Dementia 
1. The development of multiple cognitive deficits manifested by both 
memory impairment and one or more of the following 
cognitive disturbances: 
a. Aphasia (language disturbance). 
b. Apraxia (impaired ability to carry out motor activities despite 
intact motor function). 
c. Agnosia (failure to recognize objects despite intact sensory 
function). 
d. Disturbance in executive functioning  
2. The cognitive deficits in criteria 1a and 1b each cause significant 
impairment in social or occupational functioning and represent a 
significant decline from a previous level of functioning  
3. Focal neurological signs and symptoms (e.g., exaggeration of deep 
tendon reflexes, extensor plantar response, pseudobulbar palsy, gait 
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abnormalities, weakness of an extremity), or laboratory evidence 
indicative of cerebrovascular disease (e.g., multiple infarctions 
involving cortex and underlying white matter) that are judged to be 
etiologically related to the disturbance 
4. The deficits do not occur exclusively during the course of a delirium 
 
Table.4. NINDS-AIREN Criteria for the Diagnosis of Vascular 
Dementia 
1. The criteria for the clinical diagnosis of probable vascular dementia 
include all of the following: 
A. Dementia, defined by cognitive decline from a previously higher 
level of functioning and manifested by impairment of memory and of 
two or more cognitive domains (orientation, attention, language, 
visuospatial functions, executive functions, motor control, and 
praxis), preferably established by clinical examination and 
documented by neuropsychological testing; deficits should be severe 
enough to interfere with ADL not because of physical effects of 
stroke alone. 
Exclusion criteria: cases with disturbance of consciousness, delirium, 
psychosis, severe aphasia, or major sensorimotor impairment 
precluding neuropsychological testing. Also excluded are systemic 
disorders or other brain diseases (such as Alzheimer’s disease) that 
in and of themselves could account for deficits in memory and 
cognition. 
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B. Cerebrovascular disease, defined by the presence of focal signs 
on neurological examination, such as hemiparesis, lower facial 
weakness, Babinski sign, sensory deficit, hemianopia, and dysarthria 
consistent with stroke (with or without history of stroke), and 
evidence of relevant cerebrovascular disease by brain imaging 
(computed tomography or magnetic resonance imaging [MRI]) 
including multiple large-vessel infarcts or a single strategically 
placed infarct (angular gyrus, 
thalamus, basal forebrain, or posterior cerebral artery or anterior 
cerebral artery territories), as well as multiple basal ganglia and 
white matter lacunes, or extensive periventricular white matter 
lesions, or combinations thereof. 
C. A relationship between the above two disorders, manifested or 
inferred by the presence of one or more of the following: 
a. Onset of dementia within 3 months following a recognized stroke. 
b. Abrupt deterioration in cognitive functions. 
c. Fluctuating, stepwise progression of cognitive deficits 
2 Clinical features consistent with the diagnosis of probable vascular 
dementia include the following: 
A. Early presence of gait disturbance.  
B. History of unsteadiness and frequent, unprovoked falls. 
C. Early urinary frequency, urgency, and other urinary symptoms not 
explained by urological disease. 
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D. Pseudobulbar palsy. 
E. Personality and mood changes, abulia, depression, emotional 
incontinence, or other subcortical deficits including psychomotor 
retardation and abnormal executive function 
3 Features that make the diagnosis of vascular dementia uncertain or 
unlikely include the following: 
A. Early onset of memory deficit and progressive worsening of 
memory deficit and progressive worsening of memory and other 
cognitive functions, such as language (transcortical sensory aphasia), 
motor skills (apraxia), and perception (agnosia), in the absence of 
corresponding focal lesions on brain imaging. 
B. Absence of focal neurological signs, other than cognitive 
disturbance. 
C. Absence of cerebrovascular lesions on brain CT or MRI 
4 Clinical diagnosis of possible vascular dementia may be made in the 
presence of dementia (section I-A) with focal neurological signs in 
patients in whom brain imaging studies to confirm definite CVD are 
missing; or 
in the absence of clear temporal relationship between dementia and 
stroke; or in patients with subtle onset and variable course (plateau or 
improvement) of cognitive deficits and evidence of relevant CVD 
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5 Criteria for diagnosis of definite vascular dementia are: 
A. Clinical criteria for probable vascular dementia. 
B. Histopathological evidence of CVD obtained from biopsy or 
autopsy. 
C. Absence of neurofibrillary tangles and neuritic plaques exceeding 
those expected for age. 
D. Absence of other clinical or pathological evidence for dementia 
6 Classification of vascular dementia for research purposes may be 
made based on clinical, radiological, and neuropathological features, 
for subcategories or defined conditions, such as cortical vascular 
dementia, 
subcortical vascular dementia, Binswanger’s disease, and thalamic 
dementia 
 
All of these criteria sets have very different specificities and 
sensitivities. Although the ADDTC criteria might be most useful in 
clinical settings, and the NINDS-AIREN criteria the most useful in 
research settings, the lack of comparability between diagnostic criteria is 
a barrier for both of these criteria. OUTCOME 
Vascular dementia shortens life expectancy. A 5-year follow-up 
study of incident dementia cases[26] found that mortality risk was 3.3-
times higher for vascular dementia compared with non-demented people. 
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Nearly half of elderly with MCI due to vascular disease converted to 
dementia after 5 years in the Canadian Study of Health and Aging. 
Further, a follow-up study of people with Vascular Cognitive 
Impairment, Alzheimer’s Disease and ‘No cognitive impairment’, 
showed that most people with Vascular Cognitive Impairment showed 
readily detectable progression by 30 months and depressive symptoms 
and impaired judgement progressed more commonly in patients with 
Vascular Cognitive Impairment.[27] In a longitudinal study of Vascular 
Dementia due to subcortical lacunar infarcts, progressive cognitive 
decline was determined mainly by the occurrence of new vascular 
episodes and severity of the cognitive impairment at baseline,  providing 
evidence that ongoing vascular insult is responsible for progression of 
disease.[28] 
TREATMENT: 
Based on the various pathophysiological mechanisms proposed to 
underlie Vascular Cognitive Impairment, a wide range of management 
strategies have been tried to treat Vascular Cognitive Impairment, 
including control of risk factors, treating stroke mechanism, treatment of 
cognitive disorder, management of behavioral symptoms, cognitive 
retraining, and caregiver support. Attempts to reverse or delay 
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progression of cognitive impairment due to cerebrovascular disease by 
recent studies have given grounds for hope of treatment of Vascular 
Dementia.  
Decreased incidence of dementia associated with antihypertensive 
treatment using nitrendipine and perindopril has been 
demonstrated.[29,30] The Syst-Eur study found that a calcium-channel 
blocker–based  regimen for the treatment of hypertension reduced the 
incidence of dementia by 50% in older patients with isolated systolic 
hypertension studies suggest that the use of lipid-lowering agents lowers 
the risk of dementia and protects against cognitive decline.[31] Recent 
evidence suggests that prevention of Vascular Cognitive Impairment may 
be possible through physical activity.[32,33] 
In a randomised trial of 325 mg/day aspirin (versus no aspirin) 
conducted on multi-infarct dementia patients, the group of aspirin patients 
showed significantly higher cognitive scores than the untreated 
group.[34] The use of acetylcholinesterase inhibitors is based on the 
demonstration of existence of cholinergic deficits in pure Vascular 
Dementia. Donepezil tested in two double-blind, placebo-controlled trials 
on patients diagnosed with possible or probable Vascular Dementia 
showed significant improvement in cognition (ADAS-cog, MMSE) and 
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global functioning scores. [35] Galantamine, Rivastigmine, and 
Memantine have also demonstrated improvement in cognition and 
caregiver.[36,37]  
BEST PRACTICE RECOMMENDATION: VASCULAR 
COGNITIVE IMPAIRMENT AND DEMENTIA[38] 
All patients with vascular risk factors and those with clinically 
evident stroke or transient ischemic attack should be considered at high 
risk for vascular cognitive impairment. 
Patients considered at high risk for cognitive and perceptual 
impairment are those with vascular risk factors such as hypertension, age 
> 65, hyperlipidemia, diabetes, clinical stroke, neuroimaging findings of 
covert stroke or white matter disease, damage to other target organs, 
and/or those patients with cognitive or functional changes that are 
clinically evident or reported during history-taking. 
Assessment 
9 1.All patients described above should be screened for cognitive 
impairment using a validated screening tool [Evidence Level B] 
("Clinical guidelines for acute stroke management 2007," 2007; 
"Stroke Canada Optimization of Rehabilitation through Evidence 
[SCORE]," 2007).  
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9 2.Screening to investigate a person's cognitive status should 
address the following domains: arousal, alertness, attention, 
orientation, memory, language, agnosia, visuospatial/perceptual 
function, praxis and executive functions such as insight, judgment, 
social cognition, problem- solving, abstract reasoning, initiation, 
planning and, organization [Evidence Level C].  
9 3.The Montreal Cognitive Assessment is considered more sensitive 
to cognitive impairment than the Mini Mental Status Exam in 
patients with vascular cognitive impairment. Its use is 
recommended when vascular cognitive impairment is suspected 
[Evidence Level B] (Chertkow, 2007). Additional validation is 
needed for the Montreal Cognitive Assessment as well as other 
potential screening instruments such as the 5-minute protocol from 
the Vascular Cognitive Impairment Harmonization 
recommendations.  
9 4.Patients should also be screened for depression, since depression 
has been found to contribute to cognitive impairment in stroke 
patients. A validated screening tool for depression should be used 
[Evidence Level B] (Chertkow, 2007).  
9 5.Persons who have cognitive impairment detected on a screening 
test should receive additional cognitive and/or neuropsychologic 
assessments as appropriate to further guide management [Evidence 
Level B] (Chertkow, 2007).  
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Timing 
9 1.All patients considered at high risk for cognitive impairment 
should be assessed periodically as indicated by severity of clinical 
presentation, history and/or imaging abnormalities to identify 
cognitive, perceptual deficits, depression, delirium and/or changes 
in function [Evidence Level C].  
9 2.Those who have suffered a transient ischemic attack or stroke 
should have a screening assessment and, where indicated, a more 
in-depth assessment of cognitive and perceptual status at various 
transition points throughout the continuum of stroke care 
[Evidence Level C]. Transition points may include:  
a. During presentation to emergency when cognitive, 
perceptual or functional concerns are noted  
b. Upon admission to acute care, particularly if any 
evidence of delirium is noted  
c. Upon discharge home from acute care or during early 
rehabilitation if transferred to inpatient rehabilitation 
setting  
d. Periodically during in-patient rehabilitation stage 
according to client progress and to assist with 
discharge planning  
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e. Periodically following discharge to the community by 
the most appropriate community health care provider 
according to client's needs, progress and current goals 
Management 
9 1.All vascular risk factors should be managed aggressively to 
achieve optimal control [Evidence Level A] (Chertkow, 2007).  
9 2.Patients who demonstrate cognitive impairments in the screening 
process should be referred to a health care professional with 
specific expertise in this area for additional cognitive, perceptual 
and/or functional assessment to determine the severity of 
impairment and impact of deficits on function and safety in 
activities of daily living and instrumental activities of daily living, 
and to implement appropriate remedial, compensatory and/or 
adaptive intervention strategies [Evidence Level B] (Chertkow, 
2007). A team approach is recommended, and health care 
professionals may include an occupational therapist, 
neuropsychologist, psychiatrist, neurologist, geriatrician, speech–
language pathologist or social worker.  
9 3.An individualized, client-centred approach should be considered 
to facilitate resumption of desired activities such as return to work, 
leisure, driving, volunteer participation, financial management, 
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home management and other instrumental activities of daily living 
[Evidence Level C] (Chertkow, 2007).  
9 4.Intervention strategies including rehabilitation should be tailored 
according to the cognitive impairments and functional limitations 
as well as remaining cognitive abilities, as identified through in-
depth assessment and developed in relation to patients' and 
caregivers' needs and goals [Evidence Level B] . 
9 5.Strategic or compensatory training appears to be effective in the 
treatment of apraxia post stroke and should be considered 
[Evidence Level A] (Teasell, et al. 2007). The evidence for the 
effectiveness of specific interventions for cognitive impairment in 
stroke is limited and requires more research. Attention training 
may have a positive effect on specific, targeted outcomes and 
should be implemented with appropriate patients [Evidence Level 
C] (Teasell, et al., 2007). Compensatory strategies can be used to 
improve memory outcomes [Evidence Level C] (Teasell, et al., 
2007).  
9 6.Patients with evidence of depression or anxiety on screening 
should be referred and managed by an appropriate mental health 
professional [Evidence Level C]. 
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9 7.Pharmacotherapy:  
a. •Patients with evidence of vascular cognitive impairment 
should be referred to a physician with expertise in vascular 
cognitive impairment for further assessment and 
recommendations regarding pharmacotherapy [Evidence 
Level C].  
b. •Cholinesterase inhibitors should be considered for 
management of vascular cognitive impairment diagnosed 
using the National Institute of Neurological Disorders and 
Stroke (NINDS) — Association Internationale pour la 
Recherche et l'Enseignement en Nerosciences (AIREN) 
diagnostic criteria [Evidence Level B] (Chertkow, 2007).  
c. •There is fair evidence of small magnitude benefits for 
galantamine on cognition function and behaviour in mixed 
Alzheimer and cerebrovascular disease. Galantamine can be 
considered a treatment option for mixed Alzheimer and 
cerebrovascular disease [Evidence Level B] (Chertkow, 
2007).  
d. •There is fair evidence of small magnitude benefits for 
donepezil in cognitive and global outcomes, with less robust 
benefits on functional measures. Donepezil can be 
considered a treatment option for vascular dementia 
[Evidence Level B] (Chertkow, 2007). 
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Levels of Evidence 
Grade Criteria 
A Strong recommendation. Evidence from randomized controlled 
trials or meta-analyses of randomized controlled trials. Desirable 
effects clearly outweigh undesirable effects, or vice versa.  
B Single randomized controlled trial or well-designed observational 
study with strong evidence; or well-designed cohort or case–
control analytic study; or multiple time series or dramatic results 
of uncontrolled experiment. Desirable effects closely balanced 
with undesirable effects.  
C At least one well-designed, nonexperimental descriptive study  or 
expert committee reports, opinions and/or experience of respected 
authorities, including consensus from development and/or 
reviewer groups. 
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CONCLUSIONS: 
Vascular risk factors and cerebrovascular disease are now 
recognized to account for a major proportion of cognitive disorders, 
including degenerative dementias. Emphasis has shifted from diagnosis 
of Vascular Dementia based on restrictive criteria to include a broader 
spectrum of disease Vascular Cognitive Impairment that includes mixed 
dementia and cognitive impairment with no dementia. Control of vascular 
risk factors and treatment of milder forms of disease need to form the 
focus of preventive strategies. Variability exists in burden of Vascular 
Dementia, its risk factors, subtypes and outcome in different countries 
and ethnic populations and elucidating reasons for these differences will 
help in reducing burden of cognitive impairment due to cerebrovascular 
disease globally. 
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AIMS AND OBJECTIVE 
To investigate the frequency and clinical determinants of dementia 
and mild cognitive impairment following ischemic stroke. The age, 
education, pre-stroke cognitive decline, stroke volume, number of 
strokes, baseline cerebral atrophy, non-infarct white matter pathology, 
and risk factors for atherosclerosis were addressed specifically. The one 
year follow-up was done to assess the prognosis. 
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MATERIALS AND METHODS 
Subjects were ischemic stroke patients referred to neurology 
outpatient clinic of Madras Medical College during January 2009 to 
March 2011.  
Inclusion criteria 
100 consecutive patients aged ≥40 years with the diagnosis of 
ischemic stroke within previous 2 - 3 months.  
Exclusion criteria 
1. Prestroke dementia  
2. No baseline CT 
3. Neurological disorder other than the qualifying event (e.g.- 
Parkinson’s disease) 
4. Major psychiatric disorder which could lead to cognitive 
deficits 
5. Severe aphasia 
6. Severe hearing impairment 
7. Those not speaking Tamil or English  
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An ischemic stroke is defined as ‘rapidly developing clinical signs 
of focal (or global) disturbance of cerebral function, with symptoms 
lasting 24 hours or longer, with no apparent cause other than of vascular 
origin’ in which a brain CT or MRI scan does not show intracranial 
haemorrhage.  
An interval of 2-3 months following stroke onset for 
neuropsychological Testing is chosen to allow sufficient time for the 
acute stroke effects to subside. 
Assessment Procedure: 
The subjects were be subjected to structured medical and 
neurological history based on review of all available hospital charts, 
interview of the subject and a knowledgeable informant, and a structured 
clinical, neurological, neuropsychological, and neuroradiological 
evaluation.  Patients will be retested at 3, 6, and 12 months after stroke. 
At  the time of entry, the following data will be collected : (1) sex;  (2) 
age (categorized as between 40 and 59, between 60 and 69, and ≥ 70); 
(3)education; (4) cerebrovascular risk factors, including cigarette 
smoking , hypertension (treatment or two or more measurements before 
stroke of systolic pressure 140 or diastolic pressure 90 mm Hg), diabetes 
(treatment or fasting blood glucose >7.8 mmol/L before stroke), 
hypercholesterolemia (total cholesterol >6.2 mmol/L), ischemic heart 
disease (previous myocardial infarction or angina), previous history of 
41 
 
transient ischemic attack or stroke, and atrial fibrillation; and (5) presence 
of aphasia in the acute phase of stroke.  
In depth probes in the history for risk factors and  features 
suggesting of pre-morbid cognitive impairment were attempted. 
Significant past medical history if any were noted. A thorough clinical 
examination was performed at the time of first visit. A routine screening, 
which included blood sugar, urea, serum creatinine, lipid profile, four-
vessel doppler study, electrocardiogram, and echocardiogram were done 
at the time of admission.  
In addition, to assess physical and non-physical functional abilities, 
the Blessed functional activity scale (BFAS), and the Barthel index (BI) 
were administered. 
Neuropsychological Assessment: 
The study population consisted of people speaking either the Tamil 
or English. Patients were of different literacy levels. The Vascular 
Dementia Battery was offered to all patients included in this study. The 
Vascular Dementia Battery assesses six cognitive domains: attention, 
language, verbal memory, visual memory, visuoconstruction, visuomotor 
speed and executive functions. The Mini-Mental State Examination 
(MMSE) was also administered together with the Vascular Dementia 
Battery . 
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Domains  Neuropsychological tests 
Attention  Digit Span Forward 
Language Modified Boston Naming Test 
Verbal Fluency Test ( Category 
naming of animals in 1 minute ) 
Memory RAVLT  
Visuoconstruction Clock Drawing Test 
Crossing-pentagons item from 
MMSE  
Visuomotor Speed  Digit Cancellation Task 
Executive function Trail-making test B 
 
Of the 50 words used in RAVLT((Rey auditory verbal learning 
test), 42 were translated, back translated from the original list, and 
assessed for conceptual equivalence. Eight words were replaced by 
culturally appropriate words in the local language; for example, “turkey” 
was replaced by “peacock,” “ranger” was replaced by “policeman,” and 
“stocking” was replaced by “sock.”  
The patients’ performance was compared with that of a group of 
normal control subjects from previous studies. 
Neuroradiological assessment: 
All patients underwent cranial imaging, either computed 
tomography (CT) scan or magnetic resonance imaging (MRI). MRI was 
done in 61 of 100 patients, and all 100 patients underwent CT scan. 
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Infarcts were identified on neuroimaging and classified as cortical, 
subcortical, or borderzone. Cortical infarcts were defined as infarcts of 
predominantly cortical location. Subcortical infarcts were further 
classified as lacunar and nonlacunar infarcts. Lacunar infarcts were 
defined as lesions 3-15 mm in diameter,located in the deep white matter 
or the basal ganglia.Subcortical infarcts >15 mm in size were classified as 
nonlacunar. Border-zone infarcts were located in the vascular border zone 
between the anterior cerebral artery (ACA), middle cerebral artery 
(MCA), or posterior cerebral artery (PCA) or between the superficial and 
deep branches of the cerebral arteries. Stroke volume was calculated by 
using the formulae 0.5 × A × B × C.   ( A – Largest transverse diameter 
of the infarct, B – Largest perpendicular diameter of the infarct, C – 
Vertical diameter, determined by summing the thicknesses of the slices in 
which the lesion was visible )  
Diagnosis:  
For dementia (Vascular Dementia) diagnosis, a subject must have 
fulfilled NINDS-AIREN criteria (the National Institute for Neurological 
Disorders and Stroke-Association Internationale pour la Recherche et 
a'Enseignement en Neurosciences). For a diagnosis of Vascular Mild 
Cognitive Impairment, the subject must have definite impairment in one 
domain and the functional decline criterion for Vascular Dementia was 
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not met. Impairment in a cognitive domain was defined as definite 
impairment ( > 5th percentile) on at least one test.  
Vascular territory was inferred from the neurological deficit profile 
and the topography of relevant infarction on brain imaging obtained 
during their hospital stay, if positive, using the guidelines provided by 
Damasio.Territories included internal carotid, anterior cerebral, middle 
cerebral, posterior cerebral and vertebrobasilar arteries. 
Vascular Dementia Subtypes: 
Vascular Dementia was classified based on brain imaging as 
cortical Vascular Dementia in patients with multiple cortical infarcts, as 
subcortical vascular dementia when Vascular Dementia was associated 
with subcortical infarcts and/or white matter hyperintensities, or as 
cortical-subcortical Vascular Dementia in those with a combination of 
cortical infarcts and discrete subcortical infarcts/ white matter 
hyperintensities.Strategic infarct dementia was diagnosed when dementia 
could be explained by a single, strategically placed infarct. Subcortical 
vascular dementia was further classified depending on the predominant 
lesion type as subcortical vascular dementia due to subcortical infarcts, 
white matter hyperintensities, or a combination of the two. All infarcts, 
both symptomatic and silent, were taken into consideration. 
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Follow Up: 
After informed consent, patients were re-examined 3, 12, and 24 
months after stroke. In these visits, physical and neurological 
examinations, functional assessment, neuropsychologic battery, and 
diagnosis of Dementia and Vascular Mild Cognitive Impairment were 
performed. 
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RESULTS 
Prevalence of Impairment: 
Sixty percent of stroke patients were diagnosed as Vascular 
Cognitive Impairment. Twenty-three subjects were diagnosed as Vascular 
Dementia. Two subjects in the age range 40–59 years was diagnosed with 
Vascular Dementia, whereas 9 in the 60–69 years, and 12 in the ≥70 
years group had this diagnosis. The prevalence of Vascular Mild 
Cognitive Impairment was 37% and forty percent of the patients had no 
cognitive impairment. (Table.1 and 2 , Figure.1 and 2) 
 
Table. 1. Prevalence of Vascular Cognitive Impairement 
No cognitive Impairment 40 
Vascular Mild Cognitive 
Impairment 
37 
Vascular Dementia 23 
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Table .2. Prevalence of Impairment in various age groups 
 40-59 60-69 ≥70 Total 
VaMCI 6 26 5 37 
VaD 2 9 12 23 
NCI 28 8 4 40 
 
Subject Characteristics: 
Of the 176 patients with ischemic stroke screened for study 
suitability, 119 met inclusion and exclusion criteria and were entered into 
the study. The major reasons for exclusion, in order of frequency, were 
presented in Table.3. and Figure.3.   
By the time of detailed assessment at 3 months following the 
ischemic stroke, 8 were lost to follow-up (4 relocated outside Chennai 
and was not contactable, 3 died, 1 was refused for further follow-up). Of 
the 111 patients 100 completed follow-up at 1 year and 11 were lost to 
follow-up (2 died, 1 was reclassified as a patient with possible 
Alzheimer’s disease, and 8 were not contactable). 
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Table.3. Major reasons for exclusion from study. 
Serial 
No. 
 
Reasons for exclusion 
Number of 
persons 
excluded 
1. Refusal by subject or family member 17 
2. Critical medical condition 12 
3. Severe aphasia 9 
4. Pre-existing dementia clinically 5 
5. Those not peaking Tamil or English 5 
6. Neurological disorders other than qualifying 
event (e.g.- Parkinson’s disease) 
4 
7. No baseline CT 3 
8. Severe hearing impairment 2 
 
 
The demographic and functional characteristics of the study sample 
were presented in Table.4. Mean age was 66.3 years (range 48 to 85). 
29% of female patients were included in this study. Among the females 
fifty five percent had cognitive impairment whereas sixty one percent of 
male patients had the diagnosis of cognitive impairment. 
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Table .4. The demographic and functional characteristics  
 All patients 
(n=100) 
NCI 
(n=40) 
VaMCI 
(n=37) 
VaD 
(n=23) 
Age, years 66.3 61.5 67.7 72.3 
Female/Male 29/71 13/27 8/29 8/15 
Education, years 8.6 9.9 8.2 6.9 
MMSE 27.9 29.1 28.0 25.8 
Barthel Index 85 90 85 65 
 
Clinical Features: 
Stroke subjects had a mean age of 66.3 years and 71% were men. 
The numbers in the age bands 40–59, 60–69, and ≥70 years were 36, 43, 
and 21, respectively. The putative cerebrovascular risk factors were 
presented in table 5and figure 4. When the CT scans were carefully 
analysed, 68 of patients had brain infarcts, which were large infarcts in 24 
patients. (Table.6 and Figure.5) 
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Table .5.Risk Factors. 
Risk factors Stroke patients NCI VaMCI VaD 
Hypertension 56 23 19 14 
Hyper Cholesterolemia 34 13 15 6 
Smoker 51 25 18 8 
Diabetes mellitus 14 5 5 4 
Previous TIA 18 5 8 5 
Previous stroke 12 4 5 3 
Previous AMI 17 6 7 4 
Previous angina 19 6 6 7 
Atrial fibrillation 11 4 3 4 
Mean CVRF score 2.5 2.2 2.6 2.8 
Table .6. Clinical and CT brain characteristics of the sample 
 NCI  
(n=40) 
VaMCI  
(n=37) 
VaD  
(n=23) 
Clinical stroke 
Laterality (right sided) 
Lacunar infarct 
Prior CVA 
 
18 
13 
4 
 
19 
9 
5 
 
11 
5 
3 
CT Brain Infarct Volume, 
mm³ 
1430 860 4300 
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Comparison of Impaired with Non-Impaired Subjects:  
Impaired subjects, those with Vascular Dementia or Vascular Mild 
Cognitive Impairment, were older but there were no sex differences in the 
two groups. They had 1.5 years less education than the non-impaired 
subjects. The two groups did not differ significantly on any particular 
cerebrovascular risk factor except that impaired patients had a higher 
overall number of risk factors in comparison to non-impaired patients. 
The two groups did not differ significantly on the side of stroke, whether 
the strokes involved the cerebral hemisphere or brain stem/cerebellum, 
and large or lacunar strokes. Vascular Dementia subjects had a slightly 
but significantly lower score on Barthel Index, indicating greater 
disability. 
Comparison of Vascular Mild Cognitive Impairment with Vascular 
Dementia: 
The Vascular Mild Cognitive Impairment group did not differ 
significantly from Vascular Dementia on age, sex, and education but, as 
expected, the Vascular Mild Cognitive Impairment had higher scores on 
the Mini Mental Status Examination, Barthel Index, and Blessed 
functional activity scale. Cerebrovascular risk factors and their numbers 
were similar in the two groups.  
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Subtypes of Vascular Dementia: 
 Twenty three subjects were diagnosed to have Vascular Dementia 
according to NINDS-AIREN criteria. Among these 43% had subcortical 
dementia , the commonest type of vascular dementia found in this study. 
Another 26% percent had cortical-subcortical type of dementia the 
second commonest type. Two patients had vascular dementia due to 
strategic infarct one due to bilateral thalamic infarct and another due to 
anterior opercular syndrome. (Table.7 and Figure.6 )  
Table.7. Subtypes of Vascular Dementia 
Subcortical 10 (43%) 
Cortical 5 (22%) 
Cortical – Subcortical 6 (26%) 
Strategic infarct 2 (9%) 
 
Cognitive impairment and Vascular territory (Figure.7): 
When cognitive impairment was examined by specific vascular 
territory and laterality (table 8), differences were less obvious, in part 
because of small samples in some of the subgroups. Overall, cognitive 
impairment appeared most frequently with infarcts in the left anterior and 
posterior cerebral artery territories and least frequently with infarcts in the 
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vertebrobasilar artery territory. Examining vascular distribution 
independently of hemispheric side, the proportion of infarcts in the 
anterior cerebral artery territory was higher among those with cognitive 
impairment (7.6%) compared with those without (3.4%) . Comparing left-
sided, right-sided and vertebrobasilar strokes, left-sided damage was 
more common among those with cognitive impairment (n=28) compared 
with those without (n=17). 
Table. 8.  Cognitive impairment and Stroke territory 
Stroke territory 
 
Cognitive impairment 
Present(n=60) Absent(n=40) 
Left ICA 1 0 
Right ICA 0 1 
Left ACA 3 2 
Right ACA 2 2 
Left MCA 19 13 
Right MCA 18 10 
Left PCA 6 4 
Right PCA 5 2 
Vertebrobasilar 6 6 
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Frequency Of Impairment in Neuropsychological Tests: 
Comparing raw neuropsychological scores, patients with cognitive 
impairment were impaired on all 7 scored items of the 
neuropsychological battery (Table. 9).  A higher score on memory, 
attention, visuospatial functioning, language, and MMSE denotes a better 
performance. A lower score on executive functioning or visuomotor tests 
corresponds with a worse performance, as these are speed measures. On 
average, patients with cognitive impairment performed worse than those 
without such damage. I found that age influenced cognitive performance 
on all domains (older age was negatively associated with cognitive 
performance). There were no differences between patients with cognitive 
imapirment and patients without cognitive impairment in terms of 
depressive symptoms, both at 3 months and 12 months after stroke. 
Baseline and 1-year follow-up classification of the 100 patients: 
The baseline (3 months)  and 12-months results of various clinical 
parameters are  given in Table.10. 
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Table. 9. Frequency Of Impairment in Neuropsychological Tests 
Neuropsychological Tests NCI VaMCI VaD 
Digit span forward 6.1 5.0 4.2 
Modified Boston Naming Test 13.8 10.2 7.1 
Category naming of animals in 1 
minute 
17.0 13.7 10.8 
RAVLT           Delayed recall 
       Recognition 
10.1 9.0 6.2 
13.6 11.5 9.1 
Clock Drawing Test 4.7 3.8 3.2 
Trail-making test B 123 191 262 
 
Table . 10. Baseline and Follow-up results of clinical parameters 
Tests NCI VaMCI VaD 
 At 3 
months
At 12 
months
At 3 
months
At 12 
months 
At 3 
months 
At 12 
months 
MMSE 29.1 29 28.0 28.6 25.8 22.2 
Barthel Index 89.9 92.4 79.1 79.9 68.7 71.5 
BDI 9.7 9.6 13.6 13.8 15.9 15.8 
Digit span forward 6.1 6.6 5.0 6.1 4.2 4.9 
Trail-making 
Test B 
123 98 191 170 262 201 
Modified Boston 
Naming Test 
13.8 14.1 10.2 10.7 7.1 9.1 
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Of the 100 stroke patients who were reassessed, the baseline and 1-
year follow-up classification are tabulated in Table. Eighty patients had 
the same classification as at baseline. Of the 20 patients who had a 
changed classification, the majority were ‘Vascular Mild Cognitive 
Impairment’ at baseline with 10 improving to ‘No Cognitive Impairment’ 
and three deteriorating to  ‘Vascular Dementia’—an annual conversion 
rate (from ‘Vascular Mild Cognitive Impairment’ to ‘Vascular Dementia 
’) of 8%. The annual rate of deterioration from ‘No Cognitive 
Impairment’ to ‘Vascular Mild Cognitive Impairment’ was 10% but none 
of this group of patients became ‘demented’. (Table .11) 
Table .11. Baseline and Follow-up classification of Cognitive 
impairment. 
 Classification at 1-year follow-up 
NCI VaMCI VaD Total
Classification at 
baseline 
NCI 36 4 0 40 
VaMCI 10 24 3 37 
VaD 0 3 20 23 
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Relationship to functional status: 
Severity of functional impairment was significantly greater with 
cognitive impairment, measured by the Barthel Index, Blessed functional 
activity scale and NIH stroke severity scale. Moreover, dependent living 
after discharge, either at home or nursing home, was more likely (46% 
with, 27% without cognitive impairment). (Table . 12) 
Table .12. Cognitive impairment and Functional Status 
 Cognitive impairment 
Present 
(n=60) 
Absent            
(n=40) 
Functional and 
physical 
impairment 
Barthel, mean 
(SD) 
77.0 (27.9) 89.9 (17.8) 
BFAS, mean 
(SD) 
3.8 (3.9) 1.5 (2.0) 
Status after 
discharge 
Independent 32 29 
Dependent 28 11 
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DISCUSSION 
The Prevalence Rate:  
The prevalence rate of Vascular Dementia is 23% in a well 
characterised cohort of stroke subjects examined 3 months after the index 
event. All cases of Vascular Dementia, bar two, were diagnosed in those 
over 60 years. The figures are consistent with previous reports, with one 
previous study [39, 40] reporting a rate of 26.4% in individuals aged 60–
90 years, and another study [41] reporting a rate of 25% in individuals 
55–85 years old.  
Epidemiologic studies from India have shown that Vascular 
Dementia is a common form of dementia, in contrast to the West. This 
finding may be related to the overall reduced life span in Indians and the 
increasing burden of cardiovascular disease, including stroke. Recent 
observations of the decreased prevalence of Vascular Dementia in Japan, 
attributed to decreased incidence of stroke and westernization, support 
this hypothesis.  
Relationship between age and prevalence: 
Age was a significant determinant of prevalence in this study only 
when more than 60 years was used as the cut-off, i.e. the prevalence rate 
did not increase after the age of 60 years. In the New York study, subjects 
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in their 60s had a lower rate than those 70 years and older. When age was 
entered into logistic regression along with other possible determinants of 
dementia, it was no longer significant. This is possibly because age is 
correlated with cerebrovascular risk factors as well as brain imaging 
parameters such as atrophy and White mater hyperintensities. It can be 
concluded that a stroke in an older person is more likely to produce 
dementia than in someone less than 60 years. This is considered to be due 
to the additional cerebrovascular pathology in older brains, which may be 
due to previous infarctions and non-infarct ischemic changes. The role of 
Alzheimer-type pathology in older brains is another important factor, 
with post mortem examination necessary to determine its relative 
contribution. 
Vascular Dementia Prevalence: 
The prevalence rate of Vascular Dementia in this study compares 
well with other hospital-based populations [39, 40, 41] even though the 
definition of dementia used in this study was different, an issue discussed 
below. The rates of the hospital-based studies are much higher than the 
rate reported from the Framingham Study in which subjects who had 
been examined prior to the stroke were followed up for 10 years after the 
stroke [42] . The rate of dementia was 19.3% in stroke patients compared 
to 11.0% in controls, suggesting a twofold increase in risk of stroke over 
a 10- year period in the community-based sample [42] . This compares 
60 
 
with a nine fold increase reported in a cross-sectional study immediately 
following stroke [40] . It is possible that strokes in the community sample 
were less severe.  
The NINDS-AIREN [43] criteria used in this study may also have 
played a role as they are insensitive to subcortical dementia. The reason 
that I chose these criteria was to minimize the inclusion of patients with 
Alzheimer’s disease or mixed dementia in this VaD group. It is 
increasingly being recognized that vascular and Alzheimer’s disease 
pathologies frequently coexist in dementia. To exclude such patients with 
mixed dementia from a clinical study is challenging. Clinicopathologic 
studies have demonstrated that NINDS-AIREN criteria for VaD have 
high specificity for pure VaD. Therefore, within VaD group, the 
possibility of patients with coexisting Alzheimer’s pathology is 
reasonably low. Third, different criteria for diagnosing VaD may explain 
differences between series. However, NINDSAIREN criteria are the most 
widely used criteria for VaD. 
In this study, subcortical dementia due to multiple lacunar infarcts 
and/or WMHs was the most common subtype of VaD, whereas dementia 
due to multiple cortical infarcts and single strategic infarcts was less 
common. Similar patterns of VaD have been reported in Japanese and 
Western populations. 
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Impact from pre-existing dementia: 
The subjects in the Framingham Study were selected for their lack 
of dementia at baseline, which was made possible by the longitudinal 
design. In this cross-sectional study, I attempted to do this by 
retrospective assessment using the IQCODE (The Informant 
Questionnaire on Cognitive Decline in the Elderly), an informant based 
assessment of cognitive decline prior to the stroke. I excluded 5  subjects 
primarily on this criterion. In spite of this exclusion, IQCODE score 
remained a weak predictor of dementia diagnosis, and it is likely that in 
other studies that did not have such exclusion, the contribution of pre-
existing pathology was greater. Previous studies have shown that pre-
existing cognitive deficits are common in this sample [41, 44] , and post-
stroke dementia should not be considered to be new onset dementia. 
Criteria for Vascular Dementia: 
The definition of Vascular Dementia used is an important 
consideration in the interpretation of prevalence rates. The construct of 
Vascular Dementia is still evolving and the currently available criteria 
sets have low correspondence with each other [45, 46]. The criteria used 
in this study differed from those used in other studies in that memory 
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impairment was necessary for the diagnosis of Vascular Dementia. This 
is similar to the DSM-IV criteria [47] but different from the ADDTC 
[43]. Unlike the ADDTC criteria, however, the presence of two or more 
ischemic strokes or one or infarcts on CT or T 1 -weighted MRI was not 
necessary, and extensive white matter disease was sufficient for the 
diagnosis. Another feature of my diagnoses was that the 
neuropsychological and functional criteria were operationalised, and the 
significance of the vascular pathology was based on CT or MRI scans. 
CT scans were available for all patients. However, the decision whether 
the vascular pathology on brain scans was sufficient to account for the 
cognitive impairment was based on ‘clinical judgement’. The presence of 
an infarct was not considered necessary if the subject had extensive white 
matter pathology, although most subjects had a combination of the two 
kinds of lesions. Furthermore, memory impairment was not an essential 
criterion for the diagnosis of impairment or dementia. Applying the non-
memory impairment criterion to our definition of dementia would have 
changed the prevalence considerably. Six of the VaMCI subjects had 
marginal or definite memory impairment in either verbal or non-verbal 
domain, and would have met the NINDSAIREN criteria.  
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Prevalence of VaMCI: 
This study also reports the prevalence of MCI in this sample, 
presumably again of vascular origin. More than one third of stroke 
subjects met the criteria for MCI, and the combined Vascular Dementia 
and Vascular Mild Cognitive Impairment groups accounted for nearly 
60% of the sample. This suggests that the majority of stroke subjects have 
cognitive impairment, with about a quarter reaching the threshold for 
dementia diagnosis. I was interested in knowing whether the determinants 
for dementia were qualitatively or quantitatively different from those for 
Vascular Mild Cognitive Impairment. 
Stroke related factors: 
Previous studies have identified some stroke-related factors as 
determinants of dementia, in particular lacunar infarcts, left-sided lesions 
and hemispheric infarcts [39, 49]. A major dominant stroke syndrome and 
dysphasia have also been related to dementia [49, 50]. These findings 
have, however, not been consistent, with other studies failing to support 
these relationships [51], including this study. Since this study necessitated 
a demanding assessment schedule, it is likely that many severely ill 
subjects were excluded. I also excluded subjects with severe aphasia or 
non-fluency in Tamil or English because of the difficulty in obtaining 
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informed consent and assessing neuropsychological function. This may 
have contributed to the lack of a left-hemispheric bias in this dementia 
subjects.  
Risk factors and Cognitive impairment: 
Hypertension, diabetes [51], atrial fibrillation [52, 53] and other 
recognised cerebrovascular risk factors have emerged as independent risk 
factors for dementia in some studies but not others. In the Framingham 
Study, after stroke had been accounted for, exposure to individual risk 
factors did not alter the hazard ratio. The analysis in this study did 
suggest that overall cerebrovascular risk factor exposure was associated 
with cognitive impairment, but it was not significant in the combined 
regression analysis.  
Stroke Volume: 
In the brain imaging parameters, this study assessed only total 
stoke volume. It was significant (OR 1.8). Brain atrophy in this study, 
being measured after the stroke, does not accurately reflect baseline 
atrophy since it is confounded by the stroke itself. I had hypothesised that 
stroke volume and number would be independent predictors of dementia, 
and this was only partially borne out. About 70% of our subjects had this 
event as the first clinical stroke, and the multiple infarcts seen in many 
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subjects were lacunar and small in volume. Such subjects were more 
likely to have extensive White matter hyperintensities. That I found 
White matter hyperintensities to be greater in those with cognitive 
impairment is consistent with some previous reports [49, 51] and the 
literature reporting a relationship between WMHs and cognitive 
impairment [54]. It also reflects the definition of Vascular Dementia used 
by others previously: the presence of an infarct was not necessary if 
extensive White matter hyperintensities were present on MRI, and 
deficits in any two cognitive domains were sufficient for the diagnosis 
without memory being specifically affected. MRI scans were not always 
available on this subject. In such cases, CT scans were used to assess 
white matter disease. The threshold for significant white matter lesions 
was therefore high and White matter hyperintensities on T 2 –weighted 
FLAIR imaging were considered clinically significant if abnormality was 
also seen on CT scans.  
Depression: 
Some other factors that were non-significant must be commented 
upon. Depression was not significantly different in the two groups. It is 
noteworthy that in those with depression, the neuropsychological 
assessment was postponed until remission had occurred. 
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Functional status and cognitive impairment: 
The presence of cognitive impairment significantly correlated with 
dependent living after discharge from the hospital (whether requiring 
nursing home or home attendant care). Although this finding is neither 
novel nor unexpected, it emphasises the potential value of 
neuropsychological assessment of patients with stroke. Yet mental 
function tests have largely been ignored or limited in both observational 
outcome studies [55] and interventional clinical trials aimed at 
minimising neurological disability from ischemic stroke.[56] 
Follow-up: 
A more recent analysis of the Canadian Study of Health and 
Ageing cohort, showed that nearly half of those who had ‘‘vascular 
cognitive impairment without dementia’’ developed dementia within 5  
years [57]. These findings are similar to previous estimates of the 
likelihood to progression to dementia in Mild Cognitive Impairment 
(MCI) individuals [58,59]. Moreover, those who are ‘cognitively 
impaired but not demented’ had a high risk of converting to dementia, 
comparable to the results from the Canadian Study of Health and Ageing 
cohort. 
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LIMITATIONS 
This study had a number of limitations. 
9 Firstly, this is a cross-sectional study with subjects being assessed 
only after the stroke had occurred. In spite of the exclusion of 
subjects with baseline cognitive impairment prior to stroke, it 
cannot be certain that subjects with mild cognitive impairment on 
the basis of Alzheimer-type pathology did not enter the study.  
9 Secondly, a large proportion of subjects were excluded for various 
reasons, but I do not consider it to have introduced a systematic 
bias in this sample based on the analysis of the minimal data 
available on those excluded. However, the more severely affected 
patients were likely to be excluded. The prevalence rates were 
possibly underestimated by this study for this reason. 
9 Thirdly, not all subjects had an MRI scan, thereby reducing the 
power of detecting differences in neuroimaging parameters. 
9 Fourthly, genetics data were not available, and therefore the 
contribution of apolipoprotein E polymorphism to the diagnostic 
status could not be examined. 
9 I used NINDS-AIREN criteria, which are known to have low 
sensitivity. 
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CONCLUSION 
1. This study supports the high prevalence of dementia and mild 
cognitive impairment following stroke, especially in older 
individuals, and highlights the importance of cognitive reserve.  
2. The contribution of cerebrovascular risk factors is not independent 
of the stroke risk.  
3. Subcortical dementia was the most frequent subtype of Vascular 
Dementia in our hospital-based series.  
4. Stroke volume is a significant determinant of post-stroke dementia. 
5. This study suggests that cognitive performance in stroke patients 
may change over time. It also suggests that progression of 
cognitive impairment is common after stroke.  
6. The cognitive impairment is not only frequent with stroke, but also 
significantly affects functional adaptation after the acute phase. 
Efforts to modify the course of acute stroke should also take into 
account "chronic brain failure" as an outcome. 
Figure. 1. Prevalence of Vascular Cognitive Impairment 
      
 
 
Figure. 2. Prevalence of Impairment in various age groups 
  
 
 
  
Figure .3. Reasons for exclusion from study 
 
 
Figure. 4. Risk Factors 
 
 
Figure.5. Stroke Volume 
 
 
Figure. 6. Subtypes of Vascular Dementia 
 
 
 
 Figure. 7. Cognitive impairment and Vascular territory 
 
 
Figure. 8. Clock Drawing Test in a 59 years old VaMCI patient 
                      
Figure. 9. Trail Making Test – B in a 66 years old VaD patient 
 
 
Figure.10. Digit cancellation test in a 68 years old male with NCI 
     
Figure. 11. Persevaration in a 71 yeras old VaD patient 
 
 
 
 
Figure . 12. A case of anterior opercular syndrome (Unilateral)   
 
 
 
 Figure . 13. A case of Acute stroke with Dense MCA sign on right 
side 
 
 
Figure . 14.  Acute stroke–induced cytotoxic edema in the right 
cerebellar hemisphere(Diffusion- weighted MR image) 
                
Figure . 15. Enhancing infarcts. Post contrast T1-weighted image 
shows gyriform enhancement at the left insula and posterior parietal 
lobe from a subacute left MCA infarct 
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health records both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study. I agree to this access. 
However, I understand that my identity will not be revealed in any information released to 
third parties or published, unless as required under the law. I agree not to restrict the use of 
any data or results that arise from this study. 
 
I agree to take part in the above study and to comply with the instructions given during the 
study and to faithfully co-operate with the study team, and to immediately inform the study 
staff if I suffer from any deterioration in my health or well being or any unexpected or 
unusual symptoms. 
 
I hereby consent to participate in this study on “Clinical Determinants and one year follow-
up of Dementia and Mild Cognitive Impairment following Ischemic Stroke”  
 
 
I hereby give permission to undergo complete clinical examination and diagnostic tests 
including hematological, biochemical, radiological and urine examination. 
 
 
Signature / Thumb Impression ______________ Place _________ Date ____________ 
Patient’s Name and Address: 
___________________________________________________ 
Signature of the Investigator: ______________ Place _________ Date ____________ 
Study Investigator’s Name: 
________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROFORMA 
 
Clinical Determinants and one year follow-up of Dementia and Mild Cognitive 
Impairment following Ischemic Stroke 
 
Name:                                                Place: 
Age/sex:                                            Handedness:  
MIN No:                                           Education:  
Occupation:                                      Contact No: 
Complaints: 
 
 
Risk Factors and Premorbid State: 
 
 
Examination Findings: 
 
Neuropsychological Assessment: 
A. MMSE: 
B. Vascular Dementia Battery: 
Domains Neuropsychological tests Score 
Attention Digit Span Forward  
Language Modified Boston Naming Test 
Verbal Fluency Test ( Category naming of 
animals in 1 minute ) 
 
Memory RAVLT  
Visuoconstruction Clock Drawing Test 
Crossing-pentagons item from MMSE 
 
Visuomotor Speed Digit Cancellation Task  
Executive function Trail-making test B  
 
Other defects in Higher Cognitive Functions: 
 
Investigations: 
1. CT findings  
a. Site of acute lesion 
b. Volume of the acute lesion 
c. Old asymptomatic lesions 
d. Total volume of all lesions, recent and old 
e. Leukoaraiosis  
f. Presence of cortical and subcortical atrophy  
2. Blood Sugar-  F-                  PP- 
3. Sr.Cholesterol 
4. ECG 
5. Echo 
6. 4-Vessel Doppler 
7. Others: 
Follow Up: 
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1. Anbarasi 63 F 7 3478 R 25 5 5 8 6 9 1 261 7 VaD 
2. Amsam  49 F 10 243 R 30 5 9 13 8 12 5 135 6 NCI 
3. Ravi  6 M 10 23 L 30  9 13 8 12 5 233 5 VaMCI 
4. Kumari  57 F 12 19 R 29 7 10 12 10 11 5 150 2 NCI 
5. Kannan  66 M 9 57 L 29 7 8 14 7 14 4 154 6 VaMCI 
6. Manohar  63 M 6 236 L 30 6 10 12 9 13 5 170 5 NCI 
7. Kannan  48 M 10 34 L 21 3 8 10 10 14 5 293 8 VaD 
8. Gopi  54 M 5 12 L 26 5 12 9 11 13 4 190 3 NCI 
9. Mari  66 M 12 128 R 23 4 12 11 10 11 3 164 6 VaMCI 
10. Kuppan  71 M 12 35 R 22 6 13 14 7 12 4 279 1 VaD 
11. Mangai  65 F D 47 R 19 5 5 13 5 9 3 187 3 VaD 
12. Satasivam  67 M 7 13 R 30 6 10 12 12 13 5 90 5 NCI 
13. Kiruki  63 F 8 156 L 30 5 9 9 8 11 5 80 6 NCI 
14. Munian  68 M D 136 R 19 3 10 14 8 10 4 175 4 VaMCI 
15. Vijayan  61 M 5 238 L 30 8 7 9 7 11 5 178 5 VaMCI 
16. Venkat  75 F 5 12 L 29 7 8 11 8 10 3 100 5 VaMCI 
17. Vinayagan  59 M 7 13 R 30 4 9 9 7 12 4 100 5 NCI 
18. Vadivel  72 M D 123 L 30 6 10 11 8 12 5 90 6 NCI 
19. Nithya  52 F 12 129 R 29 5 11 9 12 13 5 120 6 NCI 
20. Mani  61 M 5 89 L 23 4 7 5 3 5 3 376 9 VaD 
21. Veerasamy  63 M 0 28 R 23 6 12 13 7 9 2 311 5 VaMCI 
22. Varathu  74 M 3 3 R 25 3 3 5 2 6 4 190 7 VaD 
23. Mohan  54 M 5 24 R 28 5 11 9 8 13 5 100 5 NCI 
24. Vanaja  61 F 7 256 L 30 7 10 10 8 12 5 110 6 NCI 
25. Chellappan  60 M 9 125 L 22 3 9 9 6 9 2 125 6 VaMCI 
26. Maruthai  60 M 3 28 R 30  7 10 8 12 5 120 6 VaMCI 
27. Raja  68 M 2 9 R 27 3 10 9 5 8 2 432 6 VaD 
28. Aran  62 M D 27 L 29 3 11 9 7 13 4 240 6 VaMCI 
29. Maran  58 M 10 137 R 29 5 10 9 10 11 5 100 7 NCI 
30. Ammavasai  63 M 8 123 L 30 7 8 8 9 10 3 99 7 VaMCI 
31. Mannar  76 M 11 45 L 21 3 6 12 7 11 5 403 6 VaD 
32. Meena  52 F 9 128 R 9 4 8 9 9 9 4 158 4 NCI 
33. Veerasami  49 M 11 12 L 30 5 11 12 6 19 5 95 5 VaMCI 
34. Mannar  63 M 10 245 R 30 6 9 11 11 14 4 176 3 VaMCI 
35. Mahamayi  71 F 8 13 L 30 5 10 11 12 12 4 160 3 NCI 
36. Namashi  71 M 12 2 L 30 4 7 12 10 14 4 156 7 VaMCI 
37. Nalini  68 F 9 157 R 29 5 9 10 8 12 5 140 5 NCI 
38. Alamelu  73 F D 1258 L 19 5 5 11 4 9 5 188 5 VaD 
39. Devi  62 F 0 13 R 29 5 14 10 6 9 5 200 5 VaMCI 
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40. Appusamy  65 M 5  L 26 5 12 12 7 11 3 180 5 VaMCI 
41. Malaya  57 M 8 23 L 27 7 6 9 9 12 4 211 5 VaMCI 
42. Latha  49 F D 149 L 30 7 13 17 10 14 5 130 6 NCI 
43. Lakshmi  65 F 12 23 R 30 6 13 13 12 14 5 125 7 NCI 
44. Sanmugam  77 M 3 14 L 30 6 10 12 12 13 5 120 7 NCI 
45. Rajesh  71 M 5 48 R 29 4 8 11 5 6 3 284 8 VaD 
46. Rani  67 F 4 136 R 28 7 8 9 10 12 4 124 5 VaMCI 
47. Muniammal  68 F 2 257 R 30 5 11 13 8 12 4 150 5 VaMCI 
48. Lakshmi  49 F 0 156 R 30 5 10 10 12 11 5 160 4 NCI 
49. Tamilvanan 77 M 6 13 L 28 5 9 13 6 7 3 251 8 VaD 
50. Veeratha  59 F 7 168 L 29 5 10 11 7 12 5 168 6 NCI 
51. Mariyayi  61 F 12 125 L 23 3 10 11 4 8 5 134 9 VaMCI 
52. Vinayan  61 M 5 13 L 25 7 12 13 12 12 4 190 6 NCI 
53. Kittu  73 M 4 24 R 30 6 6 14 5 9 3 129 6 VaMCI 
54. Kavitha  50 F 4 269 R 30 4 10 10 10 11 4 110 5 NCI 
55. Kuppathal  62 F 2 26 L 27 3 7 10 3 8 1 201 5 VaD 
56. Sathya  67 F 3 57 L 22 2 4 9 5 5 4 187 9 VaD 
57. Chellappan  52 M 7 23 R 30 5 7 11 6 9 2 165 5 VaMCI 
58. Raniamma  56 F D 2 R 29 6 11 12 10 13 5 115 7 NCI 
59. Dhanam  55 M 7 23 L 29 5 10 11 11 13 4 170 6 NCI 
60. Amuthan  65 M 5 13 R 29 5 8 9 11 13 4 208 7 VaMCI 
61. Malar  52 F 6  L 30 5 9 9 8 9 5 175 5 NCI 
62. Dhandabani  57 M 4 25 R 29 7 12 13 12 14 5 180 6 NCI 
63. Rajam  55 F 9 15 L 30 6 11 12 13 12 5 180 5 NCI 
64. Pandian 70 M 8 127 R 21 3 8 12 4 7 5 302 5 VaD 
65. Pavadaiammal  67 F 7 124 L 30 5 8 11 10 12 5 177 7 VaMCI 
66. Ramesh  55 M 12  L 30 5 9 12 11 12 5 140 5 NCI 
67. Narayanan  72 M 3 18 L 23 6 6 11 6 8 2 295 5 VaD 
68. Murugaye  57 F 10  L 30 6 10 10 12 12 4 120 6 NCI 
69. Rajavel  70 M 5 13 R 24 5 9 13 10 13 3 243 7 VaD 
70. Mannar  58 M 10 156 R 30 5 10 13 5 9 2 165 6 VaMCI 
71. Melakka  56 F 0 159 L 25 4 13 13 9 10 4 254 6 VaD 
72. Mallika  75 F 0 25 R 30 5 10 12 12 12 4 254 7 NCI 
73. Mayilan  78 M 1 2 R 30 5 7 8 8 12 4 100 9 VaMCI 
74. Chellayi  53 F 3  L 30 6 9 9 10 10 5 140 6 NCI 
75. Meera  51 F 7 27 L 30 7 12 13 13 13 5 85 6 NCI 
76. Nataraj  62 M 12 1 L 30 6 9 9 7 9 5 132 5 VaMCI 
77. Uma  50 F 10 1 R 30 7 12 12 13 13 5 90 8 NCI 
78. Moorthy  63 M 13 12 L 30 6 10 11 10 11 4 154 5 VaMCI 
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79. Ramar  67 M 3 25 R 24 5 4 10 3 4 2 277 5 VaD 
80. Govindhan  75 M 7  R 24 4 9 9 2 7 2 281 6 VaD 
81. Paraman  0 M 10 236 L 27 4 9 10 8 12 5 254 6 VaMCI 
82. Angujam  56 F 6  R 30 6 10 11 10 11 5 100 8 NCI 
83. Tamilanban  71 M 4 136 L 21 3 7 11 5 9 4 195 5 VaD 
84. Saroja  64 F 4 15 L 30 7 10 10 10 11 5 95 5 NCI 
85. Selvam  54 M 7 123 L 29 6 11 12 5 13 3 276 6 VaMCI 
86. Panner  55 M 9 1 L 30 5 10 9 11 11 5 200 9 NCI 
87. Ravi  69 M D 24 R 30 5 10 11 6 14 2 239 7 VaMCI 
88. Sivakami  50 F 5 1 R 29 7 11 11 11 11 4 110 5 NCI 
89. Rajakumari  51 F 7  L 25 5 12 12 13 11 5 120 6 NCI 
90. Kalaiyarasi  65 F 8 269 L 30 4 8 12 3 7 4 298 5 VaD 
91. Parthiban  68 M 5 18 R 30 6 6 9 4 11 5 129 8 VaMCI 
92. Kavi  65 M 6 19 L 30 9 7 8 9 11 5 211 9 VaMCI 
93. Alamelu  74 F 5 13 R 29 3 9 8 7 8 2 328 6 VaD 
94. Veramani  67 F 5 145 L 30 6 10 11 10 11 5 100 9 NCI 
95. Mathiyalagan  60 M 12 5 R 29 5 13 14 8 12 5 95 9 VaMCI 
96. Mani  56 M 11 237 R 25 5 12 12 10 10 5 105 6 NCI 
97. Veeran  63 M 6 137 L 24 5 7 6 2 6 3 401 4 VaD 
98. Rajathi  63 F 11 26 R 30 5 12 12 5 7 4 143 8 VaMCI 
99. Ezhil  48 F 0 25 L 30 6 11 17 8 12 5 135 3 VaMCI 
100. Ambalavanan  62 M 7 124 R 30 6 12 20 9 10 4 120 5 VaMCI 
 
KEY TO MASTER CHART 
SEX  
M-male  ,  F-female 
EDUCATION 
Number of completed years of education 
D - Degree  
RISK FACTORS  
1-Hypertension, 2-Hyper Cholesterolemia, 3-Smoker, 4-Diabetes 
mellitus, 5-Previous TIA, 6-Previous stroke, 7-Previous AMI, 8-Previous 
angina, 9-Atrial fibrillation 
LATERALISATION 
R – Right, L- Left 
TERRITORY   
1-Left ICA, 2-Right ICA, 3-Left ACA, 4-Right ACA, 5-Left MCA, 
6-Right MCA, 7-Left PCA, 8-Right PCA, 9-Vertebrobasilar 
         
      
 
       
 
 
